Current and future antiviral drug therapies of hepatitis B chronic infection

World Journal of Hepatology

Volumn 7, Issue 8, 2015, Pages 1030-1040

  Koumbi, Lemonica ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug resistance; Hepatitis B therapy; Immunotherapy; Interferon ; Nucleos(t)ide analogues

Indexed keywords

EID: 84929746938     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i8.1030     Document Type: Review

References (105)

1. Zhou Y, Holmes EC. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J Mol Evol 2007; 65: 197-205 [PMID: 17684696 DOI: 10.1007/s00239-007-0054-1]
2. Zoulim F. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res 2012; 96: 256-259 [PMID: 22999818 DOI: 10.1016/j.antiviral.2012.09.006]
3. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460 [PMID: 3768961 DOI: 10.1016/0092-8674(86)90602-1]
4. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69: 3350-3357 [PMID: 7745682]
5. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592 [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022]
6. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol 1999; 30: 536-550 [PMID: 10190742 DOI: 10.1016/S0168-8278(99)80118-4]
7. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012; 61 Suppl 1: i18-i24 [PMID: 22504916 DOI: 10.1136/gutjnl-2012-302085]
8. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
9. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
10. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am 2014; 98: 39-54 [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004]
11. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
12. Fattovich G, Tagger A, Brollo L, Giustina G, Pontisso P, Realdi G, Alberti A, Ruol A. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis 1991; 163: 400-402 [PMID: 1846394 DOI: 10.1093/infdis/163.2.40]
13. Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future challenges. QJM 2012; 105: 109-113 [PMID: 22252919 DOI: 10.1093/qjmed/hcr270]
14. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, Wong BC, Leung N, Kwong YL, Liang R, Lau GK. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603 [PMID: 16000641 DOI: 10.1136/gut.2005.070763]
15. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225 [PMID: 17287266 DOI: 10.1128/JVI.02844-06]
16. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764 [PMID: 22157327 DOI: 10.1136/gutjnl-2011-301073]
17. Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol 2008; 1: 61-75 [PMID: 21180515 DOI: 10.1177/1756283X08093944]
18. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500 [PMID: 18832247 DOI: 10.1056/NEJMra0801644]
19. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51: 787-791 [PMID: 19665816 DOI: 10.1016/j.jhep.2009.06.011]
20. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758 [PMID: 15188170 DOI: 10.1053/j.gastro.2004.03.018]
21. Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD, Tyrrell DL. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002; 76: 6356-6363 [PMID: 12021368 DOI: 10.1128/JVI.76.12.6356-6363.2002]
22. Yim HJ. [Hepatitis B virus genetic diversity and mutant]. Korean J Hepatol 2008; 14: 446-464 [PMID: 19119240 DOI: 10.3350/kjhep.2008.14.4.446]
23. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-572 [PMID: 10421670 DOI: 10.1002/hep.510300221]
24. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22 [PMID: 8988118 DOI: 10.1016/S0140-6736(96)02266-0]
25. Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68: 2671-2676 [PMID: 8139044]
26. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402 [PMID: 8633078 DOI: 10.1073/pnas.93.9.4398]
27. Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol 2012; 47: 1048-1055 [PMID: 22726105 DOI: 10.3109/00365521.2012.694902]
28. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633 [PMID: 9462667 DOI: 10.1002/hep.510270243]
29. Zoulim F, Trépo C. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 2000; 32: 1172-1174 [PMID: 11050072 DOI: 10.1053/jhep.2000.20150]
30. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-896 [PMID: 10051494 DOI: 10.1002/hep.510290321]
31. Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol 2001; 65: 257-265 [PMID: 11536231 DOI: 10.1002/jmv.2028]
32. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022 [PMID: 11231956 DOI: 10.1053/gast.2001.22461]
33. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180 [PMID: 10889166 DOI: 10.1053/gast.2000.8559]
34. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532 [PMID: 11391543 DOI: 10.1053/jhep.2001.25084]
35. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722 [PMID: 14724824 DOI: 10.1053/j.gastro.2003.09.033]
36. Sarafianos SG, Das K, Clark AD, Ding J, Boyer PL, Hughes SH, Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999; 96: 10027-10032 [PMID: 10468556 DOI: 10.1073/pnas.96.18.10027]
37. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]
38. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132: 1574-1585 [PMID: 17408658 DOI: 10.1053/j.gastro.2007.02.03]
39. Liu M, Cai H, Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 2013; 20 Suppl 1: 65-70 [PMID: 23458527 DOI: 10.1111/jvh.12066]
40. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495 [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026]
41. Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013; 19: 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19. i39.6665]
42. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]
43. Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-473 [PMID: 12143057 DOI: 10.1053/jhep.2002.34740]
44. Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol 2012; 44: 1060-1071 [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006]
45. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47: 492-498 [PMID: 17692425 DOI: 10.1016/j.jhep.2007.06.011]
46. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712 [PMID: 16941700 DOI: 10.1002/hep.21290]
47. Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007; 14: 176-182 [PMID: 17305883 DOI: 10.1111/j.1365-2893.2006.00797.x]
48. Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009; 19: 165-176 [PMID: 19374144]
49. Gregorio GV, Jones H, Choudhuri K, Vegnente A, Bortolotti F, Mieli-Vergani G, Vergani D. Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alfa. Hepatology 1996; 24: 520-523 [PMID: 8781317 DOI: 10.1002/hep.510240309]
50. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995 [PMID: 9558288 DOI: 10.1016/S0016-5085(98)70318-X]
51. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109 [PMID: 11438498 DOI: 10.1053/gast.2001.25524]
52. Carreño V, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 277-282 [PMID: 10385667 DOI: 10.1002/hep.510300117]
53. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009 [PMID: 19737568 DOI: 10.1053/j.gastro.2009.08.061]
54. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 2001; 8: 311-321 [PMID: 11555188 DOI: 10.1046/j.1365-2893.2001.00303. x]
55. Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol 2014; 20: 7707-7717 [PMID: 24976708 DOI: 10.3748/wjg.v20.i24.7707]
56. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129 [PMID: 15639293 DOI: 10.1016/S0140-6736(05)17701-0]
57. van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006; 26: 399-405 [PMID: 16629642 DOI: 10.1111/j.1478-3231.2006.01257.x]
58. Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H, Kawada N. Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol 2013; 48: 397-404 [PMID: 22850869 DOI: 10.1007/s00535-012-0645-5]
59. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 23775967 DOI: 10.1200/JCO.2012.48.5938]
60. Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 2000; 31: 1165-1175 [PMID: 10796894 DOI: 10.1053/he.2000.5982]
61. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56: 520-526 [PMID: 22037226 DOI: 10.1016/j.jhep.2011.09.018]
62. Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, Deterding K, Dumortier J, Bailly F, Esteban R, Wedemeyer H, Janssen HL, Zoulim F. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res 2011; 92: 90-95 [PMID: 21767570 DOI: 10.1016/j.antiviral.2011.07.003]
63. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012; 56 Suppl 1: S112-S122 [PMID: 22300461 DOI: 10.1016/S0168-8278(12)60012-9]
64. Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine. Antimicrob Agents Chemother 2006; 50: 955-961 [PMID: 16495257 DOI: 10.1128/AAC.50.3.955-961.2006]
65. Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-867 [PMID: 23246506 DOI: 10.1016/j.jhep.2012.12.008]
66. Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341 [PMID: 18297057 DOI: 10.1038/nbt1389]
67. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, Cuconati A, Guo H. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56: 4277-4288 [PMID: 22644022 DOI: 10.1128/AAC.00473-12]
68. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44: 422-431 [PMID: 16364492 DOI: 10.1016/j.jhep.2005.11.036]
69. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221-1228 [PMID: 24557838 DOI: 10.1126/science.1243462]
70. Weber ND, Stone D, Sedlak RH, De Silva Feelixge HS, Roychoudhury P, Schiffer JT, Aubert M, Jerome KR. AAVmediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One 2014; 9: e97579 [PMID: 24827459 DOI: 10.1371/journal.pone.009757]
71. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837 [PMID: 16530522 DOI: 10.1053/j.gastro.2006.01.001]
72. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 2009; 106: 19975-19979 [PMID: 19906987 DOI: 10.1073/pnas.0908365106]
73. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-537 [PMID: 22251702 DOI: 10.1172/JCI58847]
74. Vivekanandan P, Daniel HD, Kannangai R, Martinez-Murillo F, Torbenson M. Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol 2010; 84: 4321-4329 [PMID: 20147412 DOI: 10.1128/JVI.02280-09]
75. Guo Y, Li Y, Mu S, Zhang J, Yan Z. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication. J Med Virol 2009; 81: 1177-1183 [PMID: 19475606 DOI: 10.1002/jmv.21525]
76. Tong A, Gou L, Lau QC, Chen B, Zhao X, Li J, Tang H, Chen L, Tang M, Huang C, Wei YQ. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J Proteome Res 2009; 8: 1037-1046 [PMID: 19117405 DOI: 10.1021/pr8008622]
77. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, Hegge JO, Klein JJ, Wakefield DH, Oropeza CE, Deckert J, Roehl I, Jahn-Hofmann K, Hadwiger P, Vornlocher HP, McLachlan A, Lewis DL. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013; 21: 973-985 [PMID: 23439496 DOI: 10.1038/mt.2013.31]
78. Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res 2011; 92: 271-276 [PMID: 21871497 DOI: 10.1016/j.antiviral.2011.08.012]
79. Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 2002; 46: 3057-3060 [PMID: 12183271 DOI: 10.1128/AAC.46.9.3057-3060.2002]
80. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, Lansky DM, Jacob GS, Dwek RA. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998; 4: 610-614 [PMID: 9585237 DOI: 10.1038/nm0598-610]
81. Maini MK, Peppa D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol 2013; 4: 57 [PMID: 23459859 DOI: 10.3389/fimmu.2013.00057]
82. Barton GM. Viral recognition by Toll-like receptors. Semin Immunol 2007; 19: 33-40 [PMID: 17336545 DOI: 10.1016/j. smim.2007.01.003]
83. Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 2009; 265: 43-57 [PMID: 19093959 DOI: 10.1111/j.1365-2796.2008.02050.x]
84. Lopatin U, Wolfgang G, Tumas D, Frey CR, Ohmstede C, Hesselgesser J, Kearney B, Moorehead L, Subramanian GM, McHutchison JG. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther 2013; 18: 409-418 [PMID: 23416308 DOI: 10.3851/IMP2548]
85. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 2012; 57: 522-528 [PMID: 22617154 DOI: 10.1016/j.jhep.2012.05.004]
86. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. Hepatitis B virus suppresses toll-like receptormediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49: 1132-1140 [PMID: 19140219 DOI: 10.1002/hep.22751]
87. Pollicino T, Bellinghieri L, Restuccia A, Raffa G, Musolino C, Alibrandi A, Teti D, Raimondo G. Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha. Virology 2013; 444: 317-328 [PMID: 23890815 DOI: 10.1016/j.virol.2013.06.028]
88. Koumbi LJ, Papadopoulos NG, Anastassiadou V, Machaira M, Kafetzis DA, Papaevangelou V. Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers. Clin Vaccine Immunol 2010; 17: 1079-1085 [PMID: 20463102 DOI: 10.1128/CVI.00074-10]
89. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778 [PMID: 15791617 DOI: 10.1002/hep.20649]
90. Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res 2012; 96: 59-64 [PMID: 22884884 DOI: 10.1016/j.antiviral.2012.07.011]
91. Stross L, Günther J, Gasteiger G, Asen T, Graf S, Aichler M, Esposito I, Busch DH, Knolle P, Sparwasser T, Protzer U. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 2012; 56: 873-883 [PMID: 22487943 DOI: 10.1002/hep.25765]
92. Malanchère-Brès E, Payette PJ, Mancini M, Tiollais P, Davis HL, Michel ML. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol 2001; 75: 6482-6491 [PMID: 11413315 DOI: 10.1128/JVI.75.14.6482-6491.2001]
93. Davis HL, Suparto II, Weeratna RR, Jumintarto DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto W, Sajuthi DD. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000; 18: 1920-1924 [PMID: 10699341 DOI: 10.1016/S0264-410X(99)00443-0]
94. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trépo C, Hasan U, Chemin I. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011; 6: e26315 [PMID: 22046272 DOI: 10.1371/journal.pone.0026315]
95. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brécho C. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917-921 [PMID: 11451177 DOI: 10.1016/S0168-8278(01)00028-9]
96. Senturk H, Tabak F, Ozaras R, Erdem L, Canbakan B, Mert A, Yurdakul I. Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig Dis Sci 2009; 54: 2026-2030 [PMID: 19016327 DOI: 10.1007/s10620-008-0586-2]
97. Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31: 1197-1203 [PMID: 23306359 DOI: 10.1016/j.vaccine.2012.12.074]
98. Löhr HF, Pingel S, Böcher WO, Bernhard H, Herzog-Hauff S, Rose-John S, Galle PR. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B -restoration by exogenous interleukin-12. Clin Exp Immunol 2002; 130: 107-114 [PMID: 12296860 DOI: 10.1046/j.1365-2249.2002.01943.x]
99. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005; 42: 1028-1036 [PMID: 16250037 DOI: 10.1002/hep.20888]
100. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013; 9: e1003208 [PMID: 23516358 DOI: 10.1371/journal.ppat.1003208]
101. Shi H, Lu L, Zhang NP, Zhang SC, Shen XZ. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment. World J Gastroenterol 2012; 18: 3617-3622 [PMID: 22826629 DOI: 10.3748/wjg.v18.i27.3617]
102. Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011; 5: 644-653 [PMID: 21484123 DOI: 10.1007/s12072-011-9261-3]
103. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 1899-1905 [PMID: 11736720 DOI: 10.1046/j.1365-2036.2001.01135.x]
104. Gerin JL, Korba BE, Cote PJ, Tennant BC. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. Adv Exp Med Biol 1992; 312: 121-123 [PMID: 1514437 DOI: 10.1007/978-1-4615-3462-4_11]
105. Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009; 6: 63 [PMID: 19467157 DOI: 10.1186/1743-422X-6-63]